Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Serum Tissue Plasminogen Activator After Cycling with Blood Flow Restriction.
Vasc Biol
January 2025
K Landers, Psychology, University of Arkansas at Little Rock, Little Rock, United States.
Blood flow restriction exercise (BFRE) is a therapeutic approach traditionally used to facilitate muscular strength and hypertrophy. Emerging evidence has identified its benefits on other systems and metabolic processes. The emphasis of this study was to examine potential impact of BFRE on serum levels of tissue plasminogen activator (tPA).
View Article and Find Full Text PDFA multi-omics study of the association between insomnia with objective short sleep duration phenotype and high blood pressure.
Sleep
January 2025
Department of Sleep Medicine, Mental Health Center of Shantou University, Shantou, Guangdong, People`s Republic of China.
Study Objectives: Insomnia with objective short sleep duration is associated with increased hypertension risk. We aimed to explore the mechanism underlying the association between objective short sleep duration and hypertension in patients with chronic insomnia disorder (CID) by multi-omics.
Methods: CID was defined according to International Classification of Sleep Disorders-3, and objective short sleep was based on the median value of total sleep time of the overall subjects during an overnight polysomnography.
Proteomic Analyses in COVID-19-Associated Secondary Hemophagocytic Lymphohistiocytosis.
Crit Care Explor
February 2025
Center for Fundamental Immunology, Benaroya Research Institute, Seattle, WA.
Context: COVID-19 has been associated with features of a cytokine storm syndrome with some patients sharing features with the hyperinflammatory disorder, secondary hemophagocytic lymphohistiocytosis (sHLH).
Hypothesis: We hypothesized that proteins associated with sHLH from other causes will be associated with COVID-sHLH and that subjects with fatal COVID-sHLH would have defects in immune-related pathways.
Methods And Models: We identified two cohorts of adult patients presenting with COVID-19 at two tertiary care hospitals in Seattle, Washington in 2020 and 2021.
Effects of denosumab and zoledronic acid on postmenopausal osteoporosis, bone density, and fat-free mass.
Arch Osteoporos
January 2025
Division of Endocrinology & Metabolism, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Unlabelled: This study compared denosumab and zoledronic acid for treating osteoporosis in drug-naïve postmenopausal Korean women. Over 3 years, both drugs significantly increased bone mineral density. However, denosumab also improved fat-free mass, suggesting it may be a better initial treatment for osteoporosis with low muscle mass, assuming all other conditions remain constant.
View Article and Find Full Text PDFEarly administration of romosozumab prevents rebound of bone resorption related to denosumab withdrawal in fractured post-menopausal women: a real-world prospective study.
J Endocrinol Invest
January 2025
Department of Biomedical Sciences, Humanitas University, Pieve Emanuele (MI), Via Rita Levi Montalcini 4, Milan, Italy.
Purpose: The real-world effectiveness of switching from denosumab to romosozumab remains controversial. Sequential therapy with romosozumab was shown to be associated with inadequate suppression of bone resorption and there was anecdotal evidence of major osteoporotic fractures (MOFs) after transitioning from denosumab to romosozumab. This study evaluated the effects on bone resorption of early romosozumab administration 3 months after denosumab withdrawal in fractured women with post-menopausal osteoporosis.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!